^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MAD2L2 (Mitotic Arrest Deficient 2 Like 2)

    i
    Other names: MAD2L2, Mitotic Arrest Deficient 2 Like 2, MAD2B, REV7, MAD2 (Mitotic Arrest Deficient, Yeast, Homolog)-Like 2, Polymerase (DNA-Directed), Zeta 2, Accessory Subunit, Mitotic Spindle Assembly Checkpoint Protein MAD2B, Mitotic Arrest Deficient 2-Like Protein 2, Mitotic Arrest Deficient Homolog-Like 2, MAD2-Like Protein 2, REV7 Homolog, FANCV, POLZ2, HREV7, MAD2 Mitotic Arrest Deficient-Like 2
    12ms
    POGZ targeted by LINC01355/miR-27b-3p retards thyroid cancer progression via interplaying with MAD2L2. (PubMed, 3 Biotech)
    By reporting the first POGZ-focused ceRNA network involving noncoding RNA in THCA, our study paves the way for exploring POGZ-related pathways and developing new therapeutic strategies in cancer. The online version contains supplementary material available at 10.1007/s13205-025-04231-7.
    Journal
    |
    MAD2L2 (Mitotic Arrest Deficient 2 Like 2) • MIR27B (MicroRNA 27b)
    12ms
    Targeting the AURKB-MAD2L2 Axis Disrupts the DNA Damage Response and Glycolysis to Inhibit Colorectal Cancer Progression. (PubMed, Front Biosci (Landmark Ed))
    AURKB regulates CRC progression by modulating glycolysis and DDR pathways. Targeting the AURKB-MAD2L2 axis offers a promising therapeutic strategy for disrupting fundamental metabolic and DNA repair mechanisms in CRC.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • AURKA (Aurora kinase A) • AURKB (Aurora Kinase B) • CCNA2 (Cyclin A2) • MAD2L2 (Mitotic Arrest Deficient 2 Like 2) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B)
    1year
    REV7: a small but mighty regulator of genome maintenance and cancer development. (PubMed, Front Oncol)
    Promisingly, early studies indicate that REV7 suppression enhances sensitivity to chemotherapeutics, including cisplatin. This review aims to provide a comprehensive overview of REV7's myriad roles in genome maintenance and other functions as well as offer an updated summary of its connections to cancer and treatment resistance.
    Review • Journal
    |
    MAD2L2 (Mitotic Arrest Deficient 2 Like 2)
    |
    cisplatin
    over1year
    A pan-cancer study of ADAM9's immunological function and prognostic value particularly in liver cancer. (PubMed, Sci Rep)
    Immunohistochemistry (IHC) staining from 90 pathologically verified samples proved the positive correlation between ADAM9 and tumor stages and proved the higher expression of ADAM9 correlated genes (SNX9, APP, TNF, CDH1, ITGAV, MAD2L2) in HCC pathogenesis. In conclusion, this pan-cancer study provides a comprehensive understanding of the prognostic value of ADAM9 in various tumors emphasizing its importance to be considered as an innovative treatment approach, especially in tumor immunity shortly.
    Journal • Pan tumor
    |
    CDH1 (Cadherin 1) • ADAM9 (ADAM Metallopeptidase Domain 9) • MAD2L2 (Mitotic Arrest Deficient 2 Like 2)
    |
    ADAM9 expression
    over1year
    Somatic gene mutations involved in DNA damage response/Fanconi anemia signaling are tissue- and cell-type specific in human solid tumors. (PubMed, Front Med (Lausanne))
    Furthermore, these gene alteration patterns significantly impact patient survival and disease-free periods. Collectively, our findings not only enhance our understanding of cancer development and progression but also have significant implications for cancer patient care and prognosis, particularly in the development of effective therapeutic strategies.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • FANCF (FA complementation group F) • FANCL (FA Complementation Group L) • XRCC2 (X-Ray Repair Cross Complementing 2) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit) • FANCI (FA Complementation Group I) • FANCM (FA Complementation Group M) • MAD2L2 (Mitotic Arrest Deficient 2 Like 2) • FANCD2 (FA Complementation Group D2) • FANCE (FA Complementation Group E) • FANCG (FA Complementation Group G) • FAAP24 (FA Core Complex Associated Protein 24) • FANCB (FA Complementation Group B) • FANCC (FA Complementation Group C) • SLX4 (SLX4 Structure-Specific Endonuclease Subunit)
    |
    ATM mutation
    over1year
    HNRNPD/MAD2L2 axis facilitates lung adenocarcinoma progression and is a potential prognostic biomarker. (PubMed, Cell Signal)
    The HNRNPD/MAD2L2 axis facilitates LUAD progression and serves as a potential prognostic biomarker.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • HNRNPD (Heterogeneous Nuclear Ribonucleoprotein D) • MAD2L2 (Mitotic Arrest Deficient 2 Like 2)
    almost2years
    AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2. (PubMed, J Transl Med)
    AURKB activates MAD2L2 expression to downregulate the p53 DDR pathway, thereby promoting BC progression. Thus, AURKB may serve as a potential molecular marker and a novel anticancer therapeutic target for BC.
    Journal
    |
    AURKB (Aurora Kinase B) • MAD2L2 (Mitotic Arrest Deficient 2 Like 2)
    |
    TP53 expression • MAD2L2 overexpression
    2years
    MAD2L2, a key regulator in ovarian cancer and promoting tumor progression. (PubMed, Sci Rep)
    The upregulation of MAD2L2 also appears to inhibit the ferroptosis process, coinciding with increased mTOR signaling activity in these cells. Our study identifies MAD2L2 as a novel regulator in ovarian tumor progression and offers new insights for treating OVCA.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • MAD2L2 (Mitotic Arrest Deficient 2 Like 2)
    2years
    Identification of a Novel CD8 T cell exhaustion-related gene signature for predicting survival in hepatocellular carcinoma. (PubMed, BMC Cancer)
    The prediction model based on CD8 TEX-related genes can predict the prognosis of HCC and provide a theoretical basis for the early identification of patients with poor HCC prognosis.
    Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • NLRC5 (NLR Family CARD Domain Containing 5) • MAD2L2 (Mitotic Arrest Deficient 2 Like 2) • ANXA5 (Annexin A5)
    2years
    The promoting effect and mechanism of MAD2L2 on stemness maintenance and malignant progression in glioma. (PubMed, J Transl Med)
    Our study elucidated the role of MAD2L2 in maintaining glioblastoma stemness and promoting malignant behaviors through the regulation of c-MYC, suggesting its potential as a therapeutic target.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MAD2L2 (Mitotic Arrest Deficient 2 Like 2)
    2years
    Establishing a novel Fanconi anemia signaling pathway-associated prognostic model and tumor clustering for pediatric acute myeloid leukemia patients. (PubMed, Open Med (Wars))
    Additionally, we found a correlation between DNA repair, cell cycle, and peroxide-related metabolic events and FA-related high/low risk or cluster 1/2. In summary, our novel FA-associated prognostic models promise to enhance the prediction of pediatric AML prognosis.
    Journal
    |
    FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • FANCL (FA Complementation Group L) • MAD2L2 (Mitotic Arrest Deficient 2 Like 2) • FANCC (FA Complementation Group C)
    over2years
    Multi-omics Analysis Classifies Colorectal Cancer into Distinct Methylated Immunogenic and Angiogenic Subtypes Based on Anatomical Laterality. (PubMed, Indian J Surg Oncol)
    Our study exemplifies the translational competence and robustness of machine learning in effective translational bridging of research and clinic. The online version contains supplementary material available at 10.1007/s13193-023-01760-6.
    Journal
    |
    MAD2L2 (Mitotic Arrest Deficient 2 Like 2) • RNF217-AS1 (RNF217 Antisense RNA 1 (Head To Head)) • SOX11 (SRY-Box Transcription Factor 11) • ABCA1 (ATP Binding Cassette Subfamily A Member 1) • MIR10B (MicroRNA 10b)